亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data

医学 二甲双胍 2型糖尿病 糖尿病 内科学 2型糖尿病 不利影响 格列齐特 糖化血红素 体质指数 内分泌学
作者
Patrick Bidulka,David Gibran Lugo-Palacios,Orlagh Carroll,Stephen O’Neill,Amanda Adler,Anirban Basu,Richard J. Silverwood,Jonathan W. Bartlett,Dorothea Nitsch,Paul Charlton,Andrew H. Briggs,Liam L Smeeth,Ian Douglas,Kamlesh Khunti,Richard Grieve
出处
期刊: [BMJ]
卷期号:385: e077097-e077097 被引量:61
标识
DOI:10.1136/bmj-2023-077097
摘要

Abstract Objective To compare the effectiveness of three commonly prescribed oral antidiabetic drugs added to metformin for people with type 2 diabetes mellitus requiring second line treatment in routine clinical practice. Design Cohort study emulating a comparative effectiveness trial (target trial). Setting Linked primary care, hospital, and death data in England, 2015-21. Participants 75 739 adults with type 2 diabetes mellitus who initiated second line oral antidiabetic treatment with a sulfonylurea, DPP-4 inhibitor, or SGLT-2 inhibitor added to metformin. Main outcome measures Primary outcome was absolute change in glycated haemoglobin A 1c (HbA 1c ) between baseline and one year follow-up. Secondary outcomes were change in body mass index (BMI), systolic blood pressure, and estimated glomerular filtration rate (eGFR) at one year and two years, change in HbA 1c at two years, and time to ≥40% decline in eGFR, major adverse kidney event, hospital admission for heart failure, major adverse cardiovascular event (MACE), and all cause mortality. Instrumental variable analysis was used to reduce the risk of confounding due to unobserved baseline measures. Results 75 739 people initiated second line oral antidiabetic treatment with sulfonylureas (n=25 693, 33.9%), DPP-4 inhibitors (n=34 464 ,45.5%), or SGLT-2 inhibitors (n=15 582, 20.6%). SGLT-2 inhibitors were more effective than DPP-4 inhibitors or sulfonylureas in reducing mean HbA 1c values between baseline and one year. After the instrumental variable analysis, the mean differences in HbA 1c change between baseline and one year were −2.5 mmol/mol (95% confidence interval (CI) −3.7 to −1.3) for SGLT-2 inhibitors versus sulfonylureas and −3.2 mmol/mol (−4.6 to −1.8) for SGLT-2 inhibitors versus DPP-4 inhibitors. SGLT-2 inhibitors were more effective than sulfonylureas or DPP-4 inhibitors in reducing BMI and systolic blood pressure. For some secondary endpoints, evidence for SGLT-2 inhibitors being more effective was lacking—the hazard ratio for MACE, for example, was 0.99 (95% CI 0.61 to 1.62) versus sulfonylureas and 0.91 (0.51 to 1.63) versus DPP-4 inhibitors. SGLT-2 inhibitors had reduced hazards of hospital admission for heart failure compared with DPP-4 inhibitors (0.32, 0.12 to 0.90) and sulfonylureas (0.46, 0.20 to 1.05). The hazard ratio for a ≥40% decline in eGFR indicated a protective effect versus sulfonylureas (0.42, 0.22 to 0.82), with high uncertainty in the estimated hazard ratio versus DPP-4 inhibitors (0.64, 0.29 to 1.43). Conclusions This emulation study of a target trial found that SGLT-2 inhibitors were more effective than sulfonylureas or DPP-4 inhibitors in lowering mean HbA 1c , BMI, and systolic blood pressure and in reducing the hazards of hospital admission for heart failure ( v DPP-4 inhibitors) and kidney disease progression ( v sulfonylureas), with no evidence of differences in other clinical endpoints.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海的应助被现实的如之采纳,获得10
2秒前
风中的晓兰完成签到,获得积分10
8秒前
温暖的岂愈完成签到,获得积分10
9秒前
善良的觅荷完成签到,获得积分10
39秒前
LL完成签到 ,获得积分10
48秒前
51秒前
null的应助被科研通管家采纳,获得10
52秒前
null的应助被科研通管家采纳,获得10
52秒前
null的应助被科研通管家采纳,获得10
52秒前
秋风的应助被科研通管家采纳,获得10
52秒前
53秒前
55秒前
jb4652完成签到,获得积分10
1分钟前
1分钟前
无限寒珊完成签到,获得积分10
1分钟前
落润晓发布了新的文献求助10
1分钟前
欣喜的凡霜完成签到,获得积分10
1分钟前
Rick完成签到,获得积分10
1分钟前
tszjw168完成签到 ,获得积分10
1分钟前
拼搏淇完成签到,获得积分10
1分钟前
Lucas的应助被taka采纳,获得10
2分钟前
执着忆寒完成签到,获得积分10
2分钟前
嘻嘻哈哈的应助被活力棉花糖采纳,获得10
2分钟前
2分钟前
taka发布了新的文献求助10
2分钟前
科研通AI6.4的应助被晚星采纳,获得10
2分钟前
2分钟前
Rick发布了新的文献求助10
2分钟前
踏实的白卉完成签到,获得积分10
2分钟前
跳跃的冰安完成签到,获得积分10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
晚星发布了新的文献求助10
3分钟前
3分钟前
美满的幼旋完成签到,获得积分10
3分钟前
Darkangel发布了新的文献求助10
3分钟前
初景的应助被Angela采纳,获得20
3分钟前
阿巴阿巴完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158751
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719285
捐赠科研通 7748357
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551971
邀请新用户注册赠送积分活动 2471339